Alnylam Pharmaceuticals, Inc.
Compositions and methods for inhibiting expression of the ALAS1 gene
Last updated:
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
Status:
Grant
Type:
Utility
Filling date:
20 Sep 2018
Issue date:
8 Jun 2021